Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptus PharmaBOM:544529 +3.63%18 Net Margin % is 8.92% as of Mar. 2026, which is 24% above its 10-year median of 7.20. GuruFocus rates BOM:544529 with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 119 Medical Distribution companies, Aptus Pharma ranks better than 93.28% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Aptus Pharma's Net Income for the
six
months ended in Mar. 2026 was ₹28.7 Mil. Aptus Pharma's Revenue for the
six
months ended in Mar. 2026 was ₹322.0 Mil. Therefore, Aptus Pharma's net margin for the quarter that ended in Mar. 2026 was 8.92%.
The historical rank and industry rank for Aptus Pharma's Net Margin % or its related term are showing as below:
BOM:544529'
s Net Margin % Range Over the Past 10 Years
Min: 1.4 Med: 7.2 Max: 12.62
Current: 9.92
BOM:544529's Net Margin % is ranked better than 93.28% of 119
companies
in the Medical Distribution industry
Industry Median: 1.38
vs BOM:544529: 9.92
Aptus Pharma (BOM:544529) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Aptus Pharma Net Margin % Related Terms
Aptus Pharma Net Margin % Historical Data
* Premium members only.
The historical data trend for Aptus Pharma's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544529 vs MCK, COR, CAH: Net Margin % Comparison
For the Medical Distribution subindustry, Aptus Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptus Pharma Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Aptus Pharma's Net Margin % distribution charts can be found below:
* The bar in red indicates where Aptus Pharma's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptus Pharma (BOM:544529) has a Net Margin % of 8.92% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Aptus Pharma and its competitors. This is 24% above median its historical median of 7.20. Over the past decade, Aptus Pharma's Net Margin % has ranged from 1.40 to 12.62. According to the industry distribution chart, Aptus Pharma ranks #8 out of 119 companies in the Medical Distribution industry, placing it in the top 6.7%.
Is Aptus Pharma's Net Margin % too high?
Aptus Pharma's current Net Margin % of 8.92% is 24% above median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 12.62. The Medical Distribution industry median Net Margin % is 1.38. Aptus Pharma's value of 8.92% is 546.4% above this industry median. Based on the distribution chart, Aptus Pharma ranks #8 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Aptus Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Aptus Pharma's Net Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Aptus Pharma ranks #8 out of 119 companies for Net Margin %. This places Aptus Pharma in the top 7% of its industry — outperforming the majority of peers. The industry median Net Margin % is 1.38. Aptus Pharma's value of 8.92% is 546.4% above this benchmark. Historically, Aptus Pharma's own Net Margin % has ranged from 1.40 to 12.62 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 1.38, Aptus Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.38, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptus Pharma's current Net Margin % of 8.92% is 546.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Aptus Pharma and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptus Pharma's current Net Margin % is 8.92%, which is 24% above median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptus Pharma stock overvalued right now?
Aptus Pharma (BOM:544529) has a current Net Margin % of 8.92%. The current Net Margin % is 8.92%, which is 24% above median its 10-year median of 7.20 and 546.4% above the Medical Distribution industry median of 1.38. Aptus Pharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Aptus Pharma (BOM:544529), the current Net Margin % is 8.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. The group provides a diverse range of pharmaceutical products catering to various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness products. These are offered across a variety of dosage forms, such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets.
18GF Score
Get the complete analysis for BOM:544529
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544529 has been successfully added to your 
